Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Cleveland Clinic
With
EKR Therapeutics, Inc
More than 3 million patients yearly receive an intravenous antihypertensive agent in the US. Despite this large number of critically ill patients treated annually, little research exists in the area of acute severe hypertension, specifically hypertensive emergency, a serious condition that contributes to morbidity and mortality.
Two agents that are commonly used to treat acute hypertensive crisis include labetalol and nicardipine. Cardene may provide benefits in titration and has shown to have lower dosage adjustments compared to labetalol. Nicardipine has also shown a decreased need for additional antihypertensives when compared to labetalol in patients with stroke in a neurological ICU.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or older
Systolic blood pressure ≥180 mm Hg on 2 consecutive readings(10 minutes apart)presenting in the emergency department (ED)
You may not be if
Use of any investigational drug within 1 month prior to emergency department (ED)
Pregnant or breast-feeding females
Contraindications or allergy to beta-blockers and calcium channel blockers (see FDA approved labeling for nicardipine intravenous and labetalol)
Subjects with decompensated congestive heart failure (CHF) or with a known left ventricular ejection fraction (LVEF) \<35%
History of stroke within 30 days
Known liver failure
Suspected myocardial infarction
Suspected aortic dissection
Suspected cocaine overdose
Concurrently receiving other intravenous (I.V.) hypertensive medications